Volume 10 Issue 5
Sep.  2019
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2019  >  10(5): 570-577
Jiang Xiao, Jiang Xiaojuan, Su Ruiliang, et al. Sofosbuvir-based regimens combined with ribavirin for recipients with genotype 1 hepatitis C after liver transplantation: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 570-577. doi: 10.3969/j.issn.1674-7445.2019.05.017
Citation: Jiang Xiao, Jiang Xiaojuan, Su Ruiliang, et al. Sofosbuvir-based regimens combined with ribavirin for recipients with genotype 1 hepatitis C after liver transplantation: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 570-577. doi: 10.3969/j.issn.1674-7445.2019.05.017
shu

Sofosbuvir-based regimens combined with ribavirin for recipients with genotype 1 hepatitis C after liver transplantation: a Meta-analysis

doi: 10.3969/j.issn.1674-7445.2019.05.017

  • Lanzhou University Second Hospital, Lanzhou 730030, China

More Information
  • Corresponding author: Li Yumin, Email:liym@lzu.edu.cn
  • Received Date: 2019-06-08
    Available Online: 2021-01-19
  • Publish Date: 2019-09-15
    Abstract
  •   Objective  To evaluate whether sofosbuvir (SOF)-based direct-acting antiviral agents (DAAs) combined with ribavirin (RBV) (combined RBV) can yield benefits to the recipients infected with hepatitis C virus (HCV) genotype 1 (GT1) after liver transplantation through systematic evaluation and Meta-analysis.  Methods  Multiple databases at home and abroad were systematically searched, the literature screening was conducted according to relevant standards, the quality of literatures was evaluated and data extraction was performed. The literature was divided into two groups according to the recipients with HCV-GT1 hepatitis after liver transplantation who received the treatment combined RBV or SOF-based DAAs alone without RBV (not combined RBV). Meta-analysis of the data was carried out using Rev Man 5.3 and R3.4.3 software. The incidence of sustained virological response 12 weeks (SVR12) after therapy was evaluated.  Results  A total of 2 195 articles were retrieved, and 6 articles published in English were eventually included according to the inclusion criteria. The Meta-analysis results demonstrated that the incidence of SVR12 did not significantly differ between the combined RBV and not combined RBV groups (P=0.28). However, the incidence of anemia in the combined RBV group was significantly higher than that in the other group (P < 0.01). Both combined RBV and not combined RBV therapies were efficacious in treating HCV-GT1a and HCV-GT1b subtypes after liver transplantation with similar clinical efficacy (P=0.33). The incidence of SVR in HCV-GT1 recipients did not significantly differ after receiving 12- and 24-weeks therapy after liver transplantation (P=0.95).  Conclusions  When SOF-based DAAs regimen is adopted to treat HCV-GT1 in recipients after liver transplantation, combination with RBV not only fails to improve the virus clearance rate and bring clinical benefits, but also increases the risk of anemia in the recipients.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    WRIGHT TL, DONEGAN E, HSU HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients[J]. Gastroenterology, 1992, 103(1):317-322. doi: 10.1016/0016-5085(92)91129-R
    [2]
    KALAMBOKIS G, MANOUSOU P, SAMONAKIS D, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient[J]. Transpl Int, 2009, 22(2):172-181. DOI: 10.1111/j.1432-2277.2008.00744.x.
    [3]
    BERENGUER M, PRIETO M, RAYÓN JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation[J]. Hepatology, 2000, 32(4 Pt 1):852-858.
    [4]
    COILLY A, ROCHE B, DUCLOS-VALLÉE JC, et al. Management of HCV transplant patients with triple therapy[J]. Liver Int, 2014, 34(Suppl 1):46-52. DOI: 10.1111/liv.12406.
    [5]
    ANGELICO M, PETROLATI A, LIONETTI R, et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C[J]. J Hepatol, 2007, 46(6):1009-1017. doi: 10.1016/j.jhep.2006.12.017
    [6]
    DUMORTIER J, SCOAZEC JY, CHEVALLIER P, et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination[J]. J Hepatol, 2004, 40(4):669-674. doi: 10.1016/j.jhep.2003.12.015
    [7]
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026.
    [8]
    ELFEKI MA, ABOU MRAD R, MODARESI ESFEH J, et al. Sofosbuvir/ledipasvir without ribavirin achieved high sustained virologic response for hepatitis C recurrence after liver transplantation: two-center experience[J]. Transplantation, 2017, 101(5):996-1000. DOI: 10.1097/TP.0000000000001467.
    [9]
    ZHANG X. Direct anti-HCV agents[J]. Acta Pharm Sin B, 2016, 6(1):26-31. DOI: 10.1016/j.apsb.2015.09.008.
    [10]
    AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67(10):1477-1492. DOI: 10.1093/cid/ciy585.
    [11]
    PETRUZZIELLO A, MARIGLIANO S, LOQUERCIO G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes[J]. World J Gastroenterol, 2016, 22(34):7824-7840. DOI: 10.3748/wjg.v22.i34.7824.
    [12]
    O'LEARY JG, FONTANA RJ, BROWN K, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study[J]. Transpl Int, 2017, 30(2):196-208. DOI: 10.1111/tri.12896.
    [13]
    BROWN RS JR, O'LEARY JG, REDDY KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network[J]. Liver Transpl, 2016, 22(1):24-33. DOI: 10.1002/lt.24366.
    [14]
    CRITTENDEN NE, BUCHANAN LA, PINKSTON CM, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation[J]. Liver Transpl, 2016, 22(5):635-643. DOI: 10.1002/lt.24422.
    [15]
    NAIR S, SATAPATHY SK, GONZALEZ HC. Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant[J]. Exp Clin Transplant, 2017, 15(3):314-319. DOI: 10.6002/ect.2015.0289.
    [16]
    SAAB S, RHEEM J, JIMENEZ MA, et al. Effectiveness of ledipasvir/sofosbuvir with/without ribavarin in liver transplant recipients with hepatitis C[J]. J Clin Transl Hepatol, 2017, 5(2):101-108. DOI: 10.14218/JCTH.2016.00070.
    [17]
    PILLAI AA, WEDD J, NORVELL JP, et al. Simeprevir and sofosbuvir (SMV-SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: a real world (transplant) hepatology practice experience[J]. Am J Gastroenterol, 2016, 111(2):250-260. DOI: 10.1038/ajg.2015.422.
    [18]
    TERRAULT NA, SHIFFMAN ML, LOK AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation[J]. Liver Transpl, 2007, 13(1):122-129. doi: 10.1002/lt.20995
    [19]
    LIAO HT, TAN P, HUANG JW, et al. Ledipasvir + sofosbuvir for liver transplant recipients with recurrent hepatitis C: a systematic review and Meta-analysis[J]. Transplant Proc, 2017, 49(8):1855-1863. DOI: 10.1016/j.transproceed.2017.04.014.
    [20]
    LIAO H, TAN P, ZHU Z, et al. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: a systematic review and Meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2017, 41(3):262-271. DOI: 10.1016/j.clinre.2016.12.001.
    [21]
    LIONETTI R, CALVARUSO V, PICCOLO P, et al. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: a prospective study[J]. Clin Transplant, 2018, 32(2). DOI: 10.1111/ctr.13165.
    [22]
    PUNGPAPONG S, AQEL B, LEISE M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant[J]. Hepatology, 2015, 61(6):1880-1886. DOI: 10.1002/hep.27770.
    [23]
    FONTANA RJ, BROWN RS JR, MORENO-ZAMORA A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection[J]. Liver Transpl, 2016, 22(4):446-458. DOI: 10.1002/lt.24416.
    [24]
    CARDONA-GONZALEZ MG, GOLDMAN JD, NARAYAN L, et al. Sofosbuvir, velpatasvir, and voxilaprevir for treatment of recurrent hepatitis C virus infection after liver transplantation[J]. Hepatol Commun, 2018, 2(12):1446-1450. DOI: 10.1002/hep4.1280.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (184) PDF downloads(10) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return